UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007123
Receipt number R000008389
Scientific Title A Phase II Study of Bevacizumab (Avastin®) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy
Date of disclosure of the study information 2012/02/01
Last modified on 2019/04/24 15:56:05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase II Study of Bevacizumab (Avastin®) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy

Acronym

ADOPT study

Scientific Title

A Phase II Study of Bevacizumab (Avastin®) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapy

Scientific Title:Acronym

ADOPT study

Region

Japan


Condition

Condition

Non-sq NSCLC with previously treated

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of Bevacizumab in combination with Docetaxel or Pemetrexed for patients previously treated with combining chemotherapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

progression free survival

Key secondary outcomes

disease control rate,overall survival, and safety


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Bevasizumab + Pemetrexed

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Pathologically or cytplogically confirmed non-small cell lung cancer.
Patients with clinical stage IIIB/IV or postoperative recurrence, and unsuitable for radiotherapy.
(2) Previously treated
(3) Patients who has measurable by RECIST(ver 1.1)criteria.
(4) performance status of 0-2
(5) Age of 20 years or older
(6) Adequate organ functions
(7) Life expectancy more than 90 days
(8) Written informed consent

Key exclusion criteria

(1) Previously untreated with platinum doublet
(2) transfusion or G-CSF within 2weeks prior to enrollment
(3) Severe renal function disorder, 2+ or higher proteinuria within 2 weeks prior to enrollment
(4) History of severe drug allergy
(5) History of active double cancer within 5 years
(6) History of active severe infections
(7) Patients who have fever of over 38 degrees
(8) Continuous administration of steroid drug
(9) severe cardiac disease
(10) History of thromboembolism or severe pulmonary disease
(11) History of GI bleeding , ileus, GI ulceration
(12) massive pleural or pericardial effusion, ascites
(13) Symptomatic brain metastases
(14) Uncontrollable hypertension or diabetes mellitus
(15) Uncontrollable diarrhea
(16) Wound of unrecovery
(17) Traumatic fracture of unrecovery
(18) bleeding diathesis or receiving anticoagulant drug(except Aspirin under 324mg/day)
(19) History of pregnancy or lactation
(20) Evaluated to be ineligible by a physician for other reasons

Target sample size

34


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazunori Fujitaka

Organization

Hiroshima University Hospital

Division name

Respiratory medicine

Zip code


Address

1-2-3 kasumi , minami-ku, Hiroshima, 734-8551, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Kazunori Fujitaka

Organization

Hiroshima University Hospital

Division name

Respiratory medicine

Zip code


Address


TEL

81-082-257-5195

Homepage URL


Email



Sponsor or person

Institute

Hiroshima University Hospital
Respiratory medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2012 Year 02 Month 01 Day

Date of IRB

2012 Year 07 Month 25 Day

Anticipated trial start date

2012 Year 02 Month 01 Day

Last follow-up date

2018 Year 01 Month 05 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 01 Month 23 Day

Last modified on

2019 Year 04 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008389


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name